INDPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Indaptus Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$2.73+0.10 (+3.80%)
Close on Oct 19, 2026
- Market cap
- $317.04M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.97 (−26.22%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $317.04M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 27.88
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$15.42M
- EPS, diluted
- -$7.74
- Book value per share
- $0.10
- Diluted shares
- 116M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Operating income
-$14.77M
Net income
-$15.42M
EPS, diluted
-$7.74
Free cash flow
–
Reported periodTrailing twelve months